Cover Image

Ruxolitinib is effective in the treatment of a patient with refractory T-ALL

T-cell acute lymphoblastic leukemia (T-ALL) is a rare, aggressive T-cell malignancy. Chemotherapy alone cures only 25-45% of the cases, thus, novel treatment agents and strategies are urgently needed. We assessed the efficacy of ruxolitinib in a patient with a cutaneous relapse after allogeneic bloo...

Full description

Saved in:
Bibliographic Details
Main Authors: Jaramillo Segura, Sonia (Author) , Hennemann, Hannah Mai (Author) , Horak, Peter (Author) , Teleanu, Maria-Veronica (Author) , Heilig, Christoph E. (Author) , Hutter, Barbara (Author) , Stenzinger, Albrecht (Author) , Glimm, Hanno (Author) , Goeppert, Benjamin (Author) , Müller-Tidow, Carsten (Author) , Fröhling, Stefan (Author) , Schönland, Stefan (Author) , Schlenk, Richard Friedrich (Author)
Format: Article (Journal) Editorial
Language:English
Published: 2021
In: eJHaem
Year: 2021, Volume: 2, Issue: 1, Pages: 139-142
ISSN:2688-6146
DOI:10.1002/jha2.143
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1002/jha2.143
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/jha2.143
Get full text
Author Notes:Sonia Jaramillo, Hannah Hennemann, Peter Horak, Veronica Teleanu, Christoph E. Heilig, Barbara Hutter, Albrecht Stenzinger, Hanno Glimm, Benjamin Goeppert, Carsten Müller-Tidow, Stefan Fröhling, Stefan Schönland, Richard F. Schlenk
Description
Summary:T-cell acute lymphoblastic leukemia (T-ALL) is a rare, aggressive T-cell malignancy. Chemotherapy alone cures only 25-45% of the cases, thus, novel treatment agents and strategies are urgently needed. We assessed the efficacy of ruxolitinib in a patient with a cutaneous relapse after allogeneic blood cell transplantation of a refractory T-ALL with a Janus kinase 3 (JAK3) mutation. In this case report, we were able to show the potential benefit of the JAK inhibitor ruxolitinib in JAK3-mutated refractory T-ALL and emphasize the importance of integrating molecular markers in current treatment decision making for patients with T-ALL.
Item Description:First published: 04 December 2020
Gesehen am 07.09.2021
Physical Description:Online Resource
ISSN:2688-6146
DOI:10.1002/jha2.143

Similar Items